Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: The lower, the better?

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Mancia, Giuseppe ^a   Grassi, Guido ^a   Zanchetti, Alberto ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; NATEGLINIDE; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MACROALBUMINURIA; MICROALBUMINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; ARTICLE; BLOOD PRESSURE; DRUG EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959774465     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s244     Document Type: Review

References (25)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
2. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414
4. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009;27:923-934
5. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
6. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115-2127
7. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097 (Pubitemid 34175478)
8. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490
9. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
10. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
11. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007;50:299-305 (Pubitemid 47205777)
12. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:48-53
13. Mancia G, Messerli FH, Weber MA, et al. Association between the proportion of time under blood pressure (BP) control and cardiovascular (CV) morbidity and mortality in the VALUE trial. J Hypertens 2009;27(Suppl. 4):S327
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
15. Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201-1208 (Pubitemid 43772329)
16. Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-1369
17. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-893 (Pubitemid 46768128)
18. Messerli F, Mancia G, Weber MA, et al. Low blood pressure is associated with increased cardiovascularmorbidity (J-shape curve) in treated hypertensive patients with increased cardiovascular risk: the VALUE randomized trial. J Hypertens 2009;27:S314
19. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. Blood pressure goals and cardiovascular outcome in the diabetic population of the INVEST. J Am Coll Cardiol 2010;55:A60
20. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-892
21. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-1821
22. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202 (Pubitemid 40179960)
23. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
24. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J (Engl) 1995;108:710-717
25. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure- lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041